Literature DB >> 25368431

The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.

Leo Y Luo1, Eejung Kim2, Hiu Wing Cheung3, Barbara A Weir4, Gavin P Dunn5, Rhine R Shen6, William C Hahn7.   

Abstract

UNLABELLED: High-grade serous ovarian cancers (HGSOC) are characterized by widespread recurrent regions of copy-number gain and loss. Here, we interrogated 50 genes that are recurrently amplified in HGSOC and essential for cancer proliferation and survival in ovarian cancer cell lines. FRS2 is one of the 50 genes located on chromosomal region 12q15 that is focally amplified in 12.5% of HGSOC. We found that FRS2-amplified cancer cell lines are dependent on FRS2 expression, and that FRS2 overexpression in immortalized human cell lines conferred the ability to grow in an anchorage-independent manner and as tumors in immunodeficient mice. FRS2, an adaptor protein in the FGFR pathway, induces downstream activation of the Ras-MAPK pathway. These observations identify FRS2 as an oncogene in a subset of HGSOC that harbor FRS2 amplifications. IMPLICATIONS: These studies identify FRS2 as an amplified oncogene in a subset of HGSOC. FRS2 expression is essential to ovarian cancer cells that harbor 12q15 amplification. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25368431      PMCID: PMC4369154          DOI: 10.1158/1541-7786.MCR-14-0407

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  38 in total

1.  Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways.

Authors:  Y R Hadari; N Gotoh; H Kouhara; I Lax; J Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

2.  Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins.

Authors:  S H Ong; Y R Hadari; N Gotoh; G R Guy; J Schlessinger; I Lax
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.

Authors:  E J Lowenstein; R J Daly; A G Batzer; W Li; B Margolis; R Lammers; A Ullrich; E Y Skolnik; D Bar-Sagi; J Schlessinger
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

4.  A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway.

Authors:  H Kouhara; Y R Hadari; T Spivak-Kroizman; J Schilling; D Bar-Sagi; I Lax; J Schlessinger
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

5.  In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.

Authors:  Gavin P Dunn; Hiu Wing Cheung; Pankaj K Agarwalla; Sapana Thomas; Yulia Zektser; Alison M Karst; Jesse S Boehm; Barbara A Weir; Aaron M Berlin; Lihua Zou; Gad Getz; Joyce F Liu; Michelle Hirsch; Francisca Vazquez; David E Root; Rameen Beroukhim; Ronny Drapkin; William C Hahn
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-02       Impact factor: 11.205

6.  Synthetic lethality between CCNE1 amplification and loss of BRCA1.

Authors:  Dariush Etemadmoghadam; Barbara A Weir; George Au-Yeung; Kathryn Alsop; Gillian Mitchell; Joshy George; Sally Davis; Alan D D'Andrea; Kaylene Simpson; William C Hahn; David D L Bowtell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

7.  A genetically defined model for human ovarian cancer.

Authors:  Jinsong Liu; Gong Yang; Jennifer A Thompson-Lanza; Armand Glassman; Kimberly Hayes; Andrea Patterson; Rebecca T Marquez; Nelly Auersperg; Yinhua Yu; William C Hahn; Gordon B Mills; Robert C Bast
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

8.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

9.  Type-specific cell line models for type-specific ovarian cancer research.

Authors:  Michael S Anglesio; Kimberly C Wiegand; Nataliya Melnyk; Christine Chow; Clara Salamanca; Leah M Prentice; Janine Senz; Winnie Yang; Monique A Spillman; Dawn R Cochrane; Karey Shumansky; Sohrab P Shah; Steve E Kalloger; David G Huntsman
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

10.  Identification of druggable cancer driver genes amplified across TCGA datasets.

Authors:  Ying Chen; Jeremy McGee; Xianming Chen; Thompson N Doman; Xueqian Gong; Youyan Zhang; Nicole Hamm; Xiwen Ma; Richard E Higgs; Shripad V Bhagwat; Sean Buchanan; Sheng-Bin Peng; Kirk A Staschke; Vipin Yadav; Yong Yue; Hosein Kouros-Mehr
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240

View more
  14 in total

1.  Targeted genomic analysis of 364 adrenocortical carcinomas.

Authors:  Nikita Pozdeyev; Lauren Fishbein; Laurie M Gay; Ethan S Sokol; Ryan Hartmaier; Jeffrey S Ross; Sourat Darabi; Michael J Demeure; Adwitiya Kar; Lindsey J Foust; Katrina Koc; Daniel W Bowles; Stephen Leong; Margaret E Wierman; Katja Kiseljak-Vassiliades
Journal:  Endocr Relat Cancer       Date:  2021-08-16       Impact factor: 5.900

2.  Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.

Authors:  Qianjin Li; Omar Awad Alsaidan; Yongjie Ma; Sungjin Kim; Junchen Liu; Thomas Albers; Kebin Liu; Zanna Beharry; Shaying Zhao; Fen Wang; Iryna Lebedyeva; Houjian Cai
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

3.  Regulatory network involving miRNAs and genes in serous ovarian carcinoma.

Authors:  Haiyan Zhao; Hao Xu; Luchen Xue
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

4.  Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.

Authors:  Elizabeth Lenkiewicz; Smriti Malasi; Tara L Hogenson; Luis F Flores; Whitney Barham; William J Phillips; Alexander S Roesler; Kendall R Chambers; Nirakar Rajbhandari; Akimasa Hayashi; Corina E Antal; Michael Downes; Paul M Grandgenett; Michael A Hollingsworth; Derek Cridebring; Yuning Xiong; Jeong-Heon Lee; Zhenqing Ye; Huihuang Yan; Matthew C Hernandez; Jennifer L Leiting; Ronald M Evans; Tamas Ordog; Mark J Truty; Mitesh J Borad; Tannishtha Reya; Daniel D Von Hoff; Martin E Fernandez-Zapico; Michael T Barrett
Journal:  Cancer Res       Date:  2020-09-14       Impact factor: 12.701

5.  Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes.

Authors:  Nezar Noor Al-Hebshi; Shiyong Li; Akram Thabet Nasher; Maged El-Setouhy; Rashad Alsanosi; Jan Blancato; Christopher Loffredo
Journal:  Int J Cancer       Date:  2016-03-18       Impact factor: 7.396

Review 6.  Oncogenic Signaling Adaptor Proteins.

Authors:  Leo Y Luo; William C Hahn
Journal:  J Genet Genomics       Date:  2015-09-12       Impact factor: 4.275

7.  Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma.

Authors:  Lili Wang; Junliang Lu; Huanwen Wu; Li Wang; Xiaolong Liang; Zhiyong Liang; Tonghua Liu
Journal:  Diagn Pathol       Date:  2017-05-30       Impact factor: 2.644

8.  Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

Authors:  Robert Hanes; Iwona Grad; Susanne Lorenz; Eva W Stratford; Else Munthe; Chilamakuri Chandra Sekhar Reddy; Leonardo A Meza-Zepeda; Ola Myklebost
Journal:  Oncotarget       Date:  2016-08-23

9.  Identification of miRNA and genes involving in osteosarcoma by comprehensive analysis of microRNA and copy number variation data.

Authors:  Tao Luo; Xiangli Yi; Wei Si
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

10.  Sam68 is Overexpressed in Epithelial Ovarian Cancer and Promotes Tumor Cell Proliferation.

Authors:  Lijuan Dong; Hailuo Che; Mingmei Li; Xuepeng Li
Journal:  Med Sci Monit       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.